(AGENPARL) - Roma, 29 Giugno 2022(AGENPARL) – SILVER SPRING mer 29 giugno 2022
Drug |
Sponsor |
Medical Review |
Clinical Pharmacology Review |
Statistical Review |
BPCA or PREA or Both |
<!–
x  |
x |
Medical (PDF -x) |
Clinical pharmacology (PDF -x) |
Statistical (PDF -x) |
x |
–>
Abacavir and Lamivudine – Epzicom |
ViiV Healthcare Company |
Medical (PDF – 2.8 MB) |
Clinical pharmacology (PDF – 158 KB) |
Statistical (PDF – 693 KB) |
PREA |
Abacavir, Dolutegravir, and Lamivudine – Triumeq |
ViiV Healthcare Company |
Medical (PDF – 443 KB) |
Clinical pharmacology (PDF – 128 KB) |
None |
PREA |
Abacavir, Dolutegravir, and Lamivudine – Triumeq |
ViiV Healthcare Company c/o GlaxoSmithKline |
Medical (PDF – 389 KB)
CDTL (PDF – 798 KB)
|
Clinical pharmacology (PDF – 128 KB) |
None |
PREA |
Abacavir sulfate – Ziagen |
ViiV Healthcare Company |
Medical (PDF – 4.2 M B) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 4.7 MB) |
PREA |
Abatacept – Orencia |
Bristol-Myers Squibb Company |
Medical (PDF – 259 KB)
Medical Addendum (PDF – 469 KB)
|
Clinical pharmacology (PDF – 2.3 MB)
Clinical pharmacology (PDF – 269 KB)
|
None |
BPCA |
AbobotulinumtoxinA – Dysport |
Ipsen Bipharm Limited |
CDTL Review (PDF – 2 MB)
Medical (PDF – 3 MB)
|
None |
Statistical (PDF -2 MB) |
PREA |
AbobotulinumtoxinA – Dysport |
Ipsen Bipharm Limited |
Medical (PDF – 1 MB) |
None |
Statistical (PDF – 857 KB) |
PREA |
Acetaminophen – Ofirmev |
MallInc.krodt, Inc. |
Medical (PDF – 1.3 MB) |
Clinical pharmacology (PDF – 5.4 MB) |
Statistical (PDF -378 KB) |
PREA |
Abrocitinib – Cibinqo |
Pfizer Inc. |
Medical (PDF – 10 MB) |
None |
None |
PREA |
Acyclovir 5%, hydrocortisone 1% – Xerese |
Valeant International Bermuda |
Medical (PDF -885 KB) |
None |
None |
PREA |
Acyclovir sodium – Zovirax |
GlaxoSmithKline, LLC |
None |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
Adalimumab-adaz – Hyrimoz |
Sandoz Inc. |
Medical (PDF – 2 MB)
CDTL Review (PDF – 300 MB)
|
None |
None |
PREA |
Adalimumab-aqvh – Yusimry |
Coherus BioSciences, Inc |
Medical (PDF – 5 MB) |
None |
None |
PREA |
Adalimumab-atto – Amjevita |
Amgen Inc. |
CDTL Review (PDF – 4.3 MB)
Medical (PDF – 199K B)
Medical (PDF – 336KB)
DD Summary Review (PDF – 2.9 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 416 KB)
Statistical (PDF – 363 KB)
Statistical (PDF – 717 KB)
|
PREA |
Adalimumab-fkjp – Hulio |
Mylan Pharmaceuticals Inc. |
Medical (PDF – 2.2 MB) |
None |
None |
PREA |
Adalimumab – Humira |
AbbVie,Inc. |
Medical (PDF – 2.2 MB) |
None |
None |
PREA |
Adapalene and benzoyl peroxide – Epiduo |
Galderma Laboratories, LP |
Medical (PDF – 2.2 MB) |
Clinical pharmacology (PDF -124 KB) |
Statistical (PDF -577 KB) |
PREA |
Adapalene and benzoyl peroxide – Epiduo Forte |
Galderma Research and Development LLC |
Medical (PDF – 6.2 MB) |
Clinical pharmacology (PDF -3.6 MB) |
Statistical (PDF -1.6 MB) |
PREA |
Afatini – Gilotrif
|
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
BPCA |
Anidulafungin – Eraxis |
Vicuron Holdings LLC, a subsidiary of Pfizer Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
Albuterol sulfate – ProAir RespiClick |
Teva Pharmaceutical Products R. & D., Inc. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF -4 MB) |
Statistical (PDF -2.2 MB) |
PREA |
Albuterol sulfate – ProAir RespiClick |
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 859 KB) |
Clinical pharmacology (PDF -2.5 MB) |
Statistical (PDF -1.1 MB) |
PREA |
Aliskiren – Tekturna |
Noden Pharma DAC |
CDTL (PDF – 310 KB) |
Clinical pharmacology (PDF -3.3 MB) |
Statistical (PDF – 442 KB) |
BPCA |
Amlodipine benzoate – Katerzia
|
Silvergate Pharmaceuticals, Inc |
Medical (PDF – 46 KB) |
Clinical pharmacology (PDF – 337 KB) |
None |
PREA
|
Amphetamine – Adzenys ER |
Neos Therapeutics, Inc. |
Medical (PDF – 1.9 MB) |
Clinical pharmacology (PDF – 4.1 KB) |
None |
PREA |
Amphetamine Extended-Release Orally Disintegrating Tablets – Adzenys XR-ODT |
Neos Therapeutics, Inc. |
Medical (PDF – 470 KB) |
Clinical pharmacology (PDF -3.3 MB) |
None |
PREA |
Amphetamine – Dyanavel XR |
Tris Pharma |
Medical (PDF – 1.8 MB) |
Clinical pharmacology (PDF -4.8 MB) |
Statistical (PDF -767 KB) |
PREA |
Amphetamine – Dyanavel XR |
Tris Pharma |
Medical (PDF – 848 KB)
CDTL Review (PDF – 1 MB)
|
None |
None |
PREA |
Amphetamine sulfate – Evekeo
|
Arbor Pharmaceuticals, LLC |
Medical (PDF – 1 MB)
Medical (PDF – 155 KB)
|
Clinical pharmacology (PDF – 9 KB)
Clinical pharmacology memo (PDF – 9 KB)
|
Statistical (PDF – 532 KB) |
PREA |
Aprepitant – Emend |
Merck Sharp & Dohme Corp. |
Medical (PDF – 5.7 MB)
Medical Addendum (PDF -1.1 MB)
Medical DD memo (PDF -2.9 MB)
|
Clinical pharmacology (PDF -5 MB)
Clinical pharmacology addendum (PDF -424 KB)
|
Statistical (PDF -1.4 MB) |
PREA |
Aprepitant – Emend |
Merck Sharp & Dohme Corp. |
Medical (PDF – 553 KB) |
Clinical pharmacology (PDF – 5 MB)
Addendum (PDF -105KB)
|
Statistical (PDF -1.2MB) |
PREA |
Aprepitant – Emend |
Merck Sharp & Dohme Corp. |
Medical (PDF – 5 MB)
Medical Addendum (PDF -1.1 MB)
Medical DD memo (PDF – 2.9 MB)
|
Clinical pharmacology (PDF – 5MB)
Addendum (PDF – 105KB)
|
Statistical (PDF -1.2MB) |
PREA |
Aripiprazole – Abilify |
Otsuka |
Medical (PDF – 2.4MB) |
None |
Statistical (PDF -409KB) |
PREA |
Asenapine – Saphris |
Forest Laboratories, Inc. |
Medical (PDF – 5.4MB)
Medical (PDF – 4MB)
|
Clinical pharmacology (PDF -3.8MB) |
Statistical (PDF -3MB) |
BPCA |
Asparaginase erwinia chrysanthemi (recombinant)- rywn – RYLAZE |
Jazz Pharmaceuticals Ireland Limited |
Medical (PDF – 4 MB) |
None |
None |
PREAW |
Atazanavir and cobicistat – Evotaz |
Bristol-Myers Squibb Company |
CDTL (PDF – 402 KB) |
Clinical pharmacology (PDF -1MB) |
None |
PREA |
Atazanavir – Reyataz |
Bristol-Myers Squibb Company |
Medical (PDF – 14.1MB) |
Clinical pharmacology (PDF -1MB) |
Statistical (PDF -1.9MB) |
BOTH |
Atazanavir – Reyataz |
Bristol-Myers Squibb Company |
Medical (PDF – 1.6MB) |
Clinical pharmacology (PDF -1MB) |
Statistical (PDF -3.9MB) |
BOTH |
Atazanavir – Reyataz |
Bristol-Myers Squibb Company |
Medical (PDF – 461 KB) |
Clinical pharmacology (PDF – 318 KB) S |
Statistical (PDF – 682 KB) |
BOTH
|
Atezolizumab – TECENTRIQ
|
Genentech, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Atropine-pralidoxime – DueDote
|
Meridian Medical Technologies, Inc. |
CDTL (PDF – 402 KB)
Medical (PDF – 886 KB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Atropine Sulfate – Isopto Atropine 1% |
Alcon Research, Ltd. |
Medical (PDF – 663KB) |
Clinical pharmacology (PDF – 480KB) |
Statistical (PDF – 230KB) |
PREA |
Atropine Sulfate Ophthalmic Solution |
Akorn, Inc. |
Medical (PDF – 1.2 MB) |
Clinical pharmacology (PDF – 1MB) |
Statistical (PDF – 287KB) |
PREA |
Azelastine hydrochloride – Astepro |
Meda Pharmaceuticals |
Clinical (PDF -1 .4MB) |
None |
Statistical (PDF -473 KB |
PREA |
Azelastine hydrochloride – Astepro |
Meda Pharmaceuticals Inc. |
Medical (PDF – 2MB) |
None |
None |
PREA |
Azelastine hydrochloride and Fluticasone propionate – Dymista |
Meda Pharmaceuticals, Inc. |
Medical (PDF – 2.9MB) |
None |
Statistical (PDF -2.1MB) |
BPCA |
Baclofen – Fleqsuvy |
Azurity Pharmaceuticals, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 367 KB) |
None |
PREA |
Baclofen – Lyvispah |
Saol Therapeutics Research Limited |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 448 KB) |
None |
PREA |
Baloxavir marboxil – Xofluza
|
Shionogi, Incorporated
|
CDTL (PDF – 869 KB)
Medical (PDF – 414 KB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 2 MB) |
PREA |
Baloxavir marboxil – Xofluza |
Genentech, Incorporated |
Medical (PDF – 11 MB) |
None |
None |
PREA |
Barium sulfate – E-Z-HD |
Bracco Diagnostics Inc. |
Medical (PDF – 2.4MB) |
Clinical pharmacology (PDF -642KB) |
Statistical (PDF -988KB) |
PREA |
Barium sulfate – READI-CAT 2 & READI-CAT 2 SMOOTHIE |
Bracco Diagnostics |
Medical (PDF – 2.4MB) |
Clinical pharmacology (PDF -702KB) |
Statistical (PDF -1.2MB) |
PREA |
Barium sulfate – Varibar Pudding |
Bracco Diagnostics, Inc. |
Medical (PDF – 1MB) |
None |
None |
PREA |
Barium sulfate – Liquid E-Z-Paque |
Bracco Diagnostics, Inc. |
DD Summary Review (PDF – 233 KB) |
None |
None |
PREA |
Beclomethasone dipropionate – Qnasl |
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF -1.5MB) |
Statistical (PDF -959KB) |
PREA |
Belumosudil – Rezurock
|
Kadmon Pharmaceuticals, LLC |
Medical (PDF – 7MB) |
Non |
None |
PRE |
Belimumab – Benlysta |
Human Genome Sciences |
Medical (PDF – 6 MB) |
None |
None |
PREA |
Benralizumab – Fasenra |
AstraZeneca AB |
Medical (PDF – 1.7 MB) |
Clinical pharmacology (PDF -7 MB) |
Statistical (PDF – 2 MB) |
PREA |
Bictegravir, emtricitabine, and tenofovir alafenamide – Biktarvy |
Gilead Sciences, Inc. |
CDTL (PDF – 157 KB)
CDTL 1 (PDF – 2 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Bictegravir, emtricitabine, and tenofovir alafenamide – Biktarvy |
Gilead Sciences, Inc. |
CDTL (PDF – 2 MB) |
Clinical pharmacology (PDF – 4 MB) |
None |
PREA |
Bimatoprost ophthalmic solution, 0.03% – Latisse |
Allergan, Inc. |
DD Summary Review (PDF – 966KB)
CDTL Review (PDF – 3.4MB)
Medical (PDF – 1.6MB)
|
None |
Statistical (PDF -946KB)
Statistical Addendum (PDF – 127KB)
|
PREA |
Blinatumomab – Blincyto
|
Amgen, Inc. |
Medical (PDF – 9 MB) |
Clinical pharmacology (PDF -1.2MB) |
Statistical (PDF -374KB) |
BPCA |
Bortezomib – Velcade |
Millennium Pharmaceuticals, Inc. |
Medical (PDF – 3.5MB) |
Clinical pharmacology (PDF -1.2MB) |
Statistical (PDF -374KB) |
BPCA |
Budesonide – Entocort EC |
Elan Pharma International |
Medical (PDF – 2.9MB) |
Clinical pharmacology (PDF -2.8MB) |
Clinical pharmacology (PDF -2.8MB) |
PREA |
Brexpiprazole – Rexulti |
Otsuka Pharmaceutical Company, Ltd. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Brimonidine tartrate – Lumify |
Bausch + Lomb |
CDTL Review (PDF – 2.5 MB)
Medical (PDF – 556 KB)
|
Clinical pharmacology (PDF – 51 KB) |
Statistical (PDF – 219 KB) |
PREA |
Brivaracetam – Briviact |
UCB, Inc. |
CDTL Review (PDF – 297 KB)
Medical (PDF – 1 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA
|
Brivaracetam – Briviact |
UCB, Inc. |
Medical (PDF – 74 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Budesonide/formoterol fumarate dehydrate – Symbicort |
AstraZeneca Pharmaceuticals, LP |
Medical (PDF – 3.4 MB) |
Clinical pharmacology (PDF – 1.2 MB) |
Statistical (PDF – 2.5 MB) |
PREA |
Bupivacaine – Exparel |
Pacira Pharmaceuticals, Inc. |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Buprenorphine – Butrans |
Purdue Pharma L.P. |
Medical (PDF – 4.1 MB) |
Clinical pharmacology (PDF – 1.5 MB) |
None |
PREA |
Cabazitaxel – Jevtana |
Sanofi-Aventis U.S., L.L.C. |
Medical (PDF – 1.5 MB) |
Clinical pharmacology (PDF – 1.2 MB) |
None |
BPCA |
Cabotegravir – Apretude
|
ViiV Healthcare Company |
Medical (PDF – 8 MB) |
None |
None |
BPCA |
Calcipotriene – SORILUX Foam |
Mayne Pharma LLC |
Medical (PDF – 525 KB) |
None |
None |
PREA |
Calcipotriene – SORILUX |
Mayne Pharma LLC |
Medical (PDF – 525 KB) |
Clinical pharmacology (PDF – 1.2 MB) |
None |
PREA |
Calcipotriene and Betamethasone dipropionate – Taclonex |
LEO Pharma A/S |
Medical (PDF -5.6MB) |
Clinical pharmacology (PDF -2.4MB) |
Statistical (PDF -564KB) |
PREA |
Calcipotriene and Betamethasone dipropionate – Taclonex |
LEO Pharma A/S c/o LEO Pharma, Inc. |
Medical (PDF – 3.7MB) |
Clinical pharmacology (PDF -2.7MB) |
None |
PREA |
Calcipotriene and Betamethasone dipropionate – Taclonex |
LEO Pharma A/S |
Medical (PDF – 775 KB) |
Clinical pharmacology (PDF – 528 KB) |
None |
PREA |
Calcipotriene and betamethasone – Enstilar |
LEO Pharma A/S |
Medical (PDF – 775 KB) |
N |
None |
PREA |
Calcium Gluconate injection – Calcium Gluconate Injection |
Fresenius Kabi USA, LLC |
Medical (PDF – 4 MB)
Medical CTDL (PDF – 1.5 MB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Calcitriol – Vectical |
Galderma Laboratories, L.P. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Capecitabine – Xeloda |
Hoffmann-La Roche, Inc. |
Medical (PDF – 4MB) |
Clinical pharmacology (PDF – 1MB) |
Statistical (PDF -610KB) |
BPCA |
Carbinoxamine maleate – Karbinal ER |
Tris Pharma, Inc. |
Medical (PDF – 1.4MB) |
Clinical pharmacology (PDF – 500KB) |
None |
PREA |
Cefazolin sodium and dextrose solution – Cefazolin for Injection USP and Dextrose Injection USP in the Duplex® Container |
B. Braun Medical Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Ceftaroline fosamil – Teflaro |
Cerexa, Inc., A Subsidiary of Forest Laboratories, LLC |
Medical (PDF – 10.9MB)
Medical CTDL (PDF -1.5MB)
|
Clinical pharmacology (PDF – 3MB) |
Statistical (PDF -1.2MB) |
BPCA |
Ceftaroline fosamil – Teflaro |
Allergan Sales, LLC |
Medical (PDF – 5 MB) |
None |
None |
PREA |
Ceftazidime and Avibactam – Avycaz |
Allergan Sales, LLC |
Medical (PDF – 5 MB) |
None |
None |
PREA |
Cetirizine ophthalmic solution – Zerviate |
Nicox Ophthalmics, Inc. |
Medical Resubmission (PDF – 231 KB)
Medical (PDF – 4.9 MB)
|
Clinical pharmacology (PDF – 279 KB) |
Statistical (PDF – 580 KB) |
BOTH |
Cetirizine hydrochloride – Quzyttir |
JDP Therapeutics Inc |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Ciclesonide – Zetonna |
Takeda GmbH |
Medical (PDF – 5MB)
|
Clinical pharmacology (PDF -1.3MB) |
Statistical (PDF -674KB) |
PREA |
Cinacalcet hydrochloride – Sensipar |
|
CDTL (PDF – 2.2 MB)
Medical (PDF – 4.1 MB)
|
Clinical pharmacology (PDF – 5.6 MB) |
Statistical (PDF – 957 KB) |
PREA |
Ciprofloxacin 0.3% and Fluocinolone acetonide 0.025% – Otovel Otic Solution |
Laboratorios SALVAT, S.A. |
Medical (PDF – 4MB) |
Clinical pharmacology (PDF -632KB) |
Statistical (PDF -2MB) |
PREA |
Ciprofloxacin otic suspension – Otiprio |
Otonomy, Inc. |
Medical (PDF – 233 KB) |
Clinical pharmacology (PDF – 79 KB) |
Statistical (PDF – 213 MB |
PREA |
6% Ciprofloxacin Otic Suspension – Otiprio |
Otonomy, Inc. |
Medical (PDF – 2.3MB) |
Clinical pharmacology (PDF -97KB) |
Statistical (PDF -896KB)
Addendum (PDF -157KB
|
PREA |
Ciprofloxacin ophthalmic solution – Ciloxa |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 110 KB)
Medical (PDF – 173 KB)
|
None |
None |
BPCA |
Clascoterone – Winlevi
|
Cassiopea SpA |
Medical (PDF – 2.6MB) |
None |
None |
PREA |
Clindamycin phosphate – Xaciato |
Daré Bioscience Inc. |
Medical (PDF – 2.6MB) |
None |
None |
PREA |
Clonidine – Kapvay |
Concordia Pharms Inc. |
Medical (PDF – 2.6MB) |
None |
Statistical (PDF -2MB) |
PREA |
Cobicistat – Tybost |
Gilead Sciences, Inc. |
CDTL (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Colesevelam HCl – Welchol |
Daiichi Sankyo Inc. |
CDTL (PDF – 2MB)
Medical (PDF – 12MB)
|
Clinical pharmacology (PDF – 7MB) |
None |
PREA |
Colesevelam HCl – Welchol |
Daiichi Sankyo Inc. |
Medical (PDF – 3 MB) |
None |
Statistical (PDF – 308 KB) |
PREA |
Crisaborole Ointment, 2% – Eucrisa |
Anacor Pharmaceuticals Inc. |
CDTL Review (PDF – 2MB)
Medical (PDF – 12MB)
|
Clinical pharmacology (PDF – 7MB) |
Statistical (PDF – 1MB) |
PREA |
Cysteamine bitartrate – Procysbi |
Raptor Pharmaceuticals, Inc. |
Medical (PDF -12MB) |
Clinical pharmacology (PDF -1.3MB)
Clinical pharmacology addendum (PDF -420KB)
|
None |
BPCA |
Cysteamine bitartrate – Procysbi |
Horizon Pharma USA, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1.2MB) |
Statistical (PDF – 1MB) |
BPCA |
Dabigatran etexilate – Pradaxa |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 2 MB)
Medical (PDF – 700 KB)
|
Clinical pharmacology (PDF – 5 MB) |
None |
BPCA |
Dalbavancin hydrochloride – Dalvance
|
Allergan Sales, LLC |
Medical (PDF – 2 MB) |
None |
None |
BPCA |
Dalteparin sodium – Fragmin |
Pharmacia & Upjohn, a subsidiary of Pfizer Inc. |
Medical (PDF – 3.5 MB) |
None |
None |
PREA |
Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide – Symtuza |
Jannsen |
Medical (PDF – 3.5 MB) |
Clinical pharmacology (PDF – 1.2MB) |
None |
PREA |
Dapsone – Aczone |
Allergan, Inc. |
Medical (PDF – 3.5 MB) |
Clinical pharmacology (PDF – 2.6 MB) |
Statistical (PDF -1.3 MB) |
PREA |
Dapsone – Aczone |
Dapsone – Aczone |
Medical (PDF – 3.5 MB) |
Clinical pharmacology (PDF – 2.6 MB) |
None |
PREA |
Daptomycin – Cubicin |
Cubist Pharmaceuticals, LLC c/o Merck Sharp & Dohme Corp. |
Medical (PDF – 505 KB) |
Clinical pharmacology (PDF – 1.8 MB) |
Statistical (PDF -1.9 KB)
Statistical Addendum (PDF – 96 KB)
|
PREA |
Daptomycin – Cubicin |
Cubist Pharmaceuticals, LLC c/o Merck Sharp & Dohme Corp. |
Medical (PDF – 389 KB) |
Clinical pharmacology (PDF – 991 KB)
Clinical pharmacology Addendum (PDF – 80 KB)
|
Statistical (PDF – 374 KB) |
PREA |
Darbepoetin alfa – Aranesp |
Amgen Inc. |
Medical (PDF -1.6MB) |
None |
Statistical (PDF -280KB) |
BPCA |
Darunavir and Cobicistat – Prezcobix |
Janssen Products, LP |
Medical (PDF – 147 KB) |
Clinical pharmacology (PDF – 20 KB) |
None |
PREA |
Darunavir – Prezista |
Janssen Products, L.P. |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -1MB) |
None |
PREA |
Darunavir – Prezista |
Janssen Products, L.P. |
None |
Clinical pharmacology (PDF -352KB) |
None |
PREA |
Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide – Symtuza |
Janssen Products, L.P. |
Multi-disciplinary review (PDF – 8 MB) |
None |
None |
PREA |
Dasatinib – Sprycel
|
Bristol-Myers Squibb Company
|
CDTL Review (PDF – 1 MB)
Medical (PDF- 8 MB)
|
Clinical pharmacology (PDF – 531 KB)
|
Statistical (PDF – 19 KB) |
BPCA |
Dasiglucagon – Zegalogue |
Zealand Pharma A/S |
Medical (PDF – 5MB) |
Clinical pharmacology (PDF – 33KB)
Clinical pharmacology Addendum (PDF – 38KB)
|
Statistical (PDF – 2MB) |
PREA |
Daunorubicin and cytarabine (liposome injection) – Vyxeos |
Jazz Pharmaceuticals |
Multidisciplinary (PDF – 5 MB) |
None |
None |
PREA |
Decitabine – Dacogen |
Eisai Inc. |
Medical (PDF -2MB) |
Clinical pharmacology (PDF -1MB) |
None |
BPCA |
Deferasirox – Jadenu |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 9 MB) |
Clinical pharmacology (PDF – 1.5MB) |
Statistical (PDF – 2MB) |
PREA |
Desoximetasone – Topicort |
Taro Pharmaceuticals U.S.A., Inc. |
Medical (PDF – 221 KB) |
Clinical pharmacology (PDF – 302 KB) |
None |
PREA |
Desvenlafaxine – Pristiq |
Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. |
Medical (PDF – 103 KB)
Medical (PDF – 622 KB)
|
Clinical pharmacology (PDF – 1.5 MB) |
Statistical (PDF – 1.5 MB) |
PREA |
Deutetrabenazine – Austedo
|
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 622 KB) |
None |
None |
PREA |
Dexlansoprazole – Dexilant |
Takeda Pharmaceuticals USA Inc. |
CDTL Review (PDF-661 KB)
Medical (PDF-5 MB)
|
Clinical pharmacology (PDF-1MB) |
Statistical (PDF-50KB) |
PREA |
Dexmedtomidine hydrochloride – Precedex |
Hospira |
Medical (PDF -5MB) |
Clinical pharmacology (PDF -3.8MB) |
Statistical (PDF -1MB) |
BPCA |
Dextroamphetamine – Xelstrym |
Noven Pharmaceuticals, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Diclofenac epolamine topical system 1.3% – Flector
|
IBSA Institut Biochimique SA
|
Medical (PDF – 1 MB)
|
None |
None |
PREA |
Diclofenac potassium – Zipsor |
Assertio Therapeutics, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 453 KB) |
None |
PREA |
Difluprednate ophthalmic emulsion – Durezol |
Alcon Pharmaceuticals Ltd. c/o Alcon Research Ltd |
Medical (PDF -748KB) |
Clinical pharmacology (PDF -40KB) |
Statistical (PDF -479KB) |
BPCA |
Dolutegravir – Tivicay |
ViiV Healthcare |
Medical (PDF -7.8MB) |
Clinical pharmacology (PDF -10.8MB) |
Statistical (PDF -4MB) |
PREA |
Dolutegravir – Tivicay |
ViiV Healthcare |
Medical (PDF -1.6MB)
CDTL Review (PDF -932KB)
|
Clinical pharmacology (PDF -2.2MB) |
None |
PREA |
Dolutegravir – Tivicay PD |
ViiV Healthcare |
Medical (PDF -241KB) |
Clinical pharmacology (PDF -89KB) |
None |
PREA |
Doravirine/lamivudine/tenofovir disoproxil fumarate – Delstrigo |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
CDTL Review (PDF – 962 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Doxycycline hyclate delayed-release – Doryx |
Mayne Pharma International, Pty, Ltd. c/o Warner Chilcott US, LLC |
Medical (PDF -241KB) |
Clinical pharmacology (PDF -89KB) |
Statistical (PDF -131KB) |
PREA |
Drospirenone and estetrol tablets – Nextstellis |
Mayne Pharma LLC |
Medical (PDF – 3 MB) |
None |
None |
PREA |
Drospirenon – Slynd |
Exeltis USA, Inc |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Duloxetine – Cymbalta |
Eli Lilly and Company, Inc. |
Medical (PDF -2.2 MB) |
Clinical pharmacology (PDF -197KB) |
Statistical (PDF -2.8MB) |
PREA |
Duloxetine – Cymbalta |
Eli Lily and Company, Inc. |
Medical (PDF -2.2 MB) |
None |
None |
PREA |
Duloxetine delayed-release capsules – Drizalma Sprinkle |
Sun Pharma Global FZE |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Duloxetine hydrochloride – Cymbalta |
Eli Lilly and Company |
Medical (PDF – 8MB) |
Clinical pharmacology (PDF -959KB) |
Statistical (PDF -665KB) |
BPCA |
Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 8MB) |
None |
None |
PREA |
Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 8MB) |
None |
None |
PREA |
Econazole nitrate – Ecoza |
AmDerma Pharmaceuticals, LLC |
Medical (PDF -2 MB) |
Clinical pharmacology (PDF -2.5MB) |
Statistical (PDF -422KB) |
PREA |
Efavirenz, lamivudine, tenofovir – Symfi Lo |
Mylan Pharmaceuticals, Inc. |
Medical (PDF – 129 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Efavirenz, lamivudine, tenofovir Disoproxil Fumarate – Symfi |
Mylan Pharmaceuticals, Inc. |
Medical (541 – KB) |
None |
None |
PREA |
Efavirenz, Lamivudine and Tenofovir disoproxil fumarate |
Aurobindo Pharma Limited, India |
DD Review (PDF – 65 KB) |
Clinical pharmacology (PDF – 788 KB) |
None |
PREA |
Efavirenz, lamivudine, tenofovir disoproxil fumarate
|
Macleods Pharmaceuticals Limited, India |
Medical (PDF – 1.9MB) |
Clinical pharmacology (PDF – 788 KB) |
None |
PREA |
Efavirenz – Sustiva |
Bristol-Myers Squibb Company |
Medical (PDF -1.9MB) |
Clinical pharmacology (PDF -9.3MB) |
None |
BPCA |
Efinaconazole – Jublia |
Bausch Health Americas, Inc.
|
Medical (PDF – 538 KB) |
None |
None |
PREA |
Elbasvir and grazoprevir – Zepatier
|
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
|
|
Eltrombopag – Promacta |
Novartis Pharmaceuticals Corporation |
Medical (PDF -3.5MB) |
Clinical pharmacology (PDF -1.2MB) |
Statistical (PDF -1MB) |
BPCA |
Eltrombopag – Promacta |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 58 KB) |
None |
None |
PREA |
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide – Genvoya |
Gilead Sciences, Inc. |
Medical (PDF -13.4MB) |
Clinical pharmacology (PDF -24.2MB) |
Statistical (PDF -2.2MB) |
PREA |
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide – Genvoya |
Gilead Sciences, Inc. |
Medical (PDF – 642 KB) |
Clinical pharmacology (PDF – 242 KB) |
None |
PREA |
Elvitegravir, Cobicistat, Emtricitabine/Tenofovir Disoproxil Fumarate – Stribild |
Gilead Sciences, Inc. |
CTDL Review (PDF -359KB) |
Clinical pharmacology (PDF – 462KB) |
None |
PREA |
Emtricitabine, Rilpivirine, and Tenofovir alafenamide – Odefsey |
Gilead Sciences, Inc. |
Medical (PDF -310KB)
CTDL Review (PDF -578KB)
|
Clinical pharmacology (PDF -5MB)
Clinical pharmacology addendum (PDF -297KB)
|
None |
PREA |
Emtricitabine, Rilpivirine, and Tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
Medical (PDF -1.27MB)
Addendum (PDF -572KB)
|
Clinical pharmacology (PDF -7.6MB) |
Statistical (PDF -1.9MB) |
PREA |
Emtricitabine, Rilpivirine, and Tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
Medical (PDF -1.27MB) |
Clinical pharmacology (PDF -7.6MB) |
Statistical (PDF -1.9MB) |
PREA |
Emtricitabine and tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
Medical (PDF – 642 KB) |
Clinical pharmacology (PDF -145KB) |
None |
PREA |
Emtricitabine and tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
CDTL Review (PDF – 2 MB) |
None |
None |
PREA |
Emtricitabine, Rilpivirine, and Tenofovir isoproxil fumarate – Complera |
Gilead Sciences, Inc. |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -145KB) |
None |
PREA |
Emtricitabine and Tenofovir disoproxil fumarate – Truvada |
Gilead Sciences, Inc. |
Medical (PDF -501KB) |
Clinical pharmacology (PDF -189KB) |
None |
PREA |
Entecavir – Baraclude |
Bristol-Myers Squibb Company |
Medical (PDF -3.4MB) |
Clinical pharmacology (PDF -3MB) |
Statistical (PDF -660KB) |
BPCA |
Entrectinib – Rozlytrek |
Genentech |
Medical (PDF – 23 MB) |
None |
None |
BPCA |
Erlotinib – Tarceva |
OSI Pharmaceuticals, LLC |
Medical (PDF -6.2MB) |
Clinical pharmacology (PDF -2.2MB) |
None |
BPCA |
Epinephrine – Auvi-Q |
Kaleo, Inc. |
Medical (PDF – 1.8 MB) |
None |
None |
PREA |
Escitalopram oxalate – Lexapro |
Forest Laboratories, Inc. |
Medical (PDF -218KB) |
None |
None |
BPCA |
Eslicarbazepine acetate – Aptiom |
Sunovion Pharmaceutical Inc. |
CDTL Review (PDF – 593 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 2.9 KB) |
None |
PREA |
Eszopiclone – Lunesta |
Sunovion Pharmaceuticals, Inc. |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -883KB) |
None |
BPCA |
Etafilcon – Theravision with Ketotifen |
Johnson & Johnson Vision Care, Inc. |
DD Review (PDF – 2 MB)
Medical (PDF – 460 KB)
|
None |
Statistical (PDF – 3 MB) |
PREA |
Etanercept – Enbrel |
Immunex Corporation, a wholly-owned subsidiary of Amgen Inc. |
Medical (PDF – 4.8 MB)
DD Review (PDF – 568 KB)
CDTL Review PDF – 504 KB)
|
Clinical pharmacology (PDF – 702 KB) |
Statistical (PDF – 444 KB) |
PREA |
Etanercept-szzs – Erelzi |
Sandoz Inc. |
Medical (PDF – 1.7 MB) |
Clinical pharmacology (PDF – 4.7 MB) |
Statistical (PDF – 432 KB) |
PREA |
Etanercept-szzs – Erelzi |
Sandoz Inc. |
CDTL Review PDF – 504 KB)
|
None |
None |
PREA |
Etravirine – Intelence |
Janssen Products, LP |
Medical (PDF -1.4MB) |
Clinical pharmacology (PDF -1.7MB) |
None |
PREA |
Etravirine – Intelence |
Janssen Products, LP |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF – 896 KB) |
None |
BPCA |
Everolimus tablets for oral suspension – Afinitor Disperz |
Novartis Pharmaceuticals Corporation |
Medical (PDF -10MB) |
Clinical pharmacology (PDF -2MB) |
None |
BPCA |
Evolocumab – Repatha |
Amgen, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 1 MB) |
PREA |
Exenatide – Bydureon |
AstraZeneca Pharmaceuticals AB C/O AstraZeneca Pharmaceuticals LP |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 1 MB) |
BPCA |
Fenfluramine HCl – Fintepla |
Zogenix, Inc. |
Medical (PDF – 588 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Ferric oxyhydroxide – Velphoro |
Vifor Fresenius Medical Care Renal Pharma France |
Medical (PDF – 1 MB) |
None |
None |
BPCA |
Ferric carboxymaltose -Injectafer |
American Regent, Inc. |
Medical (PDF – 613 KB) |
Clinical pharmacology (PDF – 7 MB) |
None |
PREA |
Fesoterodine fumarate – Toviaz |
Pfizer, Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 6 MB) |
Statistical (PDF – 300 KB) |
PREA |
Fidaxomicin – Dificid
|
Cubist Pharmaceuticals LLC |
Medical (PDF -3.8MB) |
None |
None |
BPCA |
Filgrastim-sndz – Zarxio |
Sandoz, Inc. |
Medical (PDF -3.8MB)
DD Review (PDF -86KB)
TL Review (PDF -422KB)
|
Clinical pharmacology (PDF -2.75MB)
Addendum (PDF – 1.1MB)
|
Statistical (PDF -6742KB) |
PREA |
Filgrastim-aafi – Nivestym |
Hospira, Inc. |
CDTL Review (PDF – 746 KB)
Medical (PDF – 245 KB)
|
Clinical pharmacology (PDF – 661 KB) |
Statistical (PDF – 377 KB) |
PREA |
Finafloxacin otic suspension – Xtoro |
Alcon Research, Ltd. |
Medical (PDF -6.8MB) |
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -3.2MB) |
BPCA |
Fingolimod – Gilenya |
Novartis Pharmaceuticals Corporation |
CDTL Review (PDF – 2 MB)
Medical (PDF – 3.8 MB)
|
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -3.2MB) |
PREA |
Fluticasone furoate inhalation powder – Arnuity Ellipta |
GlaxoSmithKline |
Medical (PDF -8.6MB) |
Clinical pharmacology (PDF -5.7MB) |
Statistical (PDF -1.9) |
PREA |
Fluticasone furoate – Arnuity Ellipta |
GlaxoSmithKline |
Medical (PDF – 956 KB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 507 KB) |
PREA |
Fluticasone Furoate/Umeclidinium/Vilanterol – Trelegy Ellipta |
GlaxoSmithKline Intellectual Property Development Ltd. England |
Medical (PDF -3MB) |
None |
None |
PREA |
Fluticasone propionate Lotion – Cutivate |
Fougera Pharmaceuticals Inc. |
Medical (PDF -3MB) |
Clinical pharmacology (PDF -1MB) |
Statistical (PDF -317MB) |
PREA |
Fluticasone propionate Lotion – Cutivate |
Fougera Pharmaceuticals Inc. |
Medical (PDF -1.2MB) |
Clinical pharmacology (PDF -1.4MB) |
None |
PREA |
Fluticasone propionate/salmeterol xinafoate – Advair HFA |
GlaxoSmithKline |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF -267KB) |
Statistical (PDF -52 KB) |
PREA |
Fluticasone propionate – ArmonAir RespiClick |
Teva Pharmaceutical Industries Ltd. |
Medical (PDF -10 MB) |
Clinical pharmacology (PDF – 4.3MB) |
Statistical (PDF -1.2 KB) |
PREA |
Fluticasone propionate – ArmonAir RespiClick
|
Teva Pharmaceutical Industries Ltd. c/o: Teva Branded Pharmaceutical Products R&D Inc. |
Medical (PDF – 6 MB) |
None |
None |
PREA |
Fluticasone propionate/salmeterol – AirDuo |
Teva Pharmaceutical Industries Ltd. |
Medical (PDF -10 MB) |
Clinical pharmacology (PDF – 4.3 MB) |
Statistical (PDF -1.2 KB) |
PREA |
Formoterol fumarate and mometasone furoate – Dulera
|
Merck Sharp & Dohme Corp. |
Medical (PDF -10 MB) |
|
|
|
Fosaprepitant – Emend |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 7 MB) |
Statistical (PDF – 662 KB) |
BPCA |
Fosphenytoin sodium – Cerebyx |
Parke-Davis, a Division of Pfizer, Inc. |
CDTL Review (PDF – 390 KB)
Medical (PDF – 1.5 MB)
|
Clinical pharmacology (PDF – 5 MB) |
None |
PREA |
Gadobutrol – Gadavist |
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF -958KB) |
Clinical pharmacology (PDF -2.2MB) |
Statistical (PDF -422 KB) |
PREA |
Gadobutrol – Gadavist |
Bayer Healthcare Pharmaceuticals, Inc. |
Medical (PDF -7MB) |
None |
Statistical (PDF -782 KB) |
PREA |
Gadoterate meglumine – Dotarem |
Guerbet LLC |
Medical (PDF -3MB) |
Clinical pharmacology (PDF -768KB) |
Statistical (PDF -1.2 MB) |
PREA |
Gadoterate meglumine – Dotarem |
Guerbet LLC |
Medical (PDF 1.3 MB) |
Clinical pharmacology (PDF – 1.5 MB) |
Statistical (PDF – 398 KB) |
PREA |
Gadoteridol – ProHance |
Bracco Diagnostics, Inc |
Medical (PDF – 3 MB) |
None |
None |
PREA |
Gadoxetate disodium – Eovist |
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF -1.2MB) |
Clinical pharmacology (PDF -1.5MB) |
None |
PREA |
Gatifloxacin ophthalmic solution – Zymar |
Allergan, Inc. |
Medical (PDF – 78 KB) |
None |
None |
PREA |
Gatifloxacin – Zymar |
Allergan, Inc. |
DDTL (PDF – 428 KB) |
None |
None |
Both |
Glecaprevir and Pibrentasvir – Mavyret |
AbbVie Inc. |
CTDL (PDF – 2 MB)
CTDL Addendum (PDF – 187 KB)
|
Clinical pharmacology (PDF – 409 KB) |
Statistical (PDF – 439 KB) |
PREA |
Glecaprevir and Pibrentasvir – Mavyret |
AbbVie Inc. |
Medical (PDF – 78 KB) |
None |
None |
PREA |
Glecaprevir and pibrentasvir – Mavyret |
AbbVie, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
BPCA |
Glucagon – Gvoke |
Xeris Pharmaceuticals, Inc. |
Medical (PDF – 3 MB)
CTDL Review (PDF – 3 MB
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
PREA |
Glucagon – Baqsimi |
Eli Lilly and Company |
Medical (PDF – 3 MB)
CTDL Review (PDF – 3 MB
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
PREA |
Glycopyrronium – Qbrexza |
Dermira, Inc. |
Medical (PDF – 6 MB) |
None |
None |
PREA
|
Golimumab – Simponi |
Janssen Biotech, Inc. |
Medical (PDF – 3.1 MB)
|
Clinical pharmacology (PDF – 307 KB) |
Statistical (PDF – 1.1 MB) |
PREA |
Golimumab – Simponi Aria |
Janssen Biotech, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Guanfacine – Intuniv |
Shire |
Medical (PDF – 2 MB)
CTDL Review (PDF -134 KB)
|
Clinical pharmacology (PDF – 330 KB) |
Statistical (PDF – 544 KB) |
Both |
Guanfacine – Intuniv |
Shire |
Medical (PDF -3MB) |
Clinical pharmacology (PDF – 667KB) |
Statistical (PDF -3MB) |
PREA |
Halobetasol – Propionate Ultravate |
Sun Pharmaceutical Industries, Inc. |
Medical (PDF – 150 KB) |
Clinical pharmacology (PDF – 303 KB) |
None |
PREA |
Halobetasol Propionate – Lexette
|
Mayne Pharma LLC |
Medical (PDF – 249 KB) |
Clinical pharmacology (PDF – 752 KB) |
None |
BPCA |
Ibrexafungerp – Brexafemme |
SCYNEXIS, Inc. |
Medical (PDF – 10 MB) |
None |
None |
PREA |
Ibuprofen – Caldolor |
Cumberland Pharmaceuticals, Inc. |
DD Summary Review (PDF -669KB)
Medical (PDF -3MB)
|
Clinical pharmacology (PDF -3.7MB) |
Statistical (PDF -378KB) |
PREA |
IncobotulinumtoxinA – Xeomin |
Merz Pharmaceuticals GmbH |
Medical (PDF – 2 MB) |
None |
Statistical (PDF – 1 MB) |
PREA |
Indocyanine green for Injection – Spy Agent Green
|
Novadaq Technologies ULC |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Indocyanine green for Injection – Spy Agent Green
|
Novadaq Technologies ULC |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Infliximab-axxq – Avsola |
Amgen, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Infliximab-dyyb – Inflectra |
Celltrion, Inc. |
Medical (PDF -5.3MB)
Addendum (PDF – 1MB)
|
None |
Statistical (PDF -2MB) |
PREA |
Infliximab-abda – Renflexis |
Samsung Bioepsis Co., Ltd |
CDTL Review (PDF – 1 MB)
Medical (PDF – 3.5 MB)
Medical 2(PDF – 267 KB)
Medical 3 (PDF – 93 KB)
|
Clinical pharmacology (PDF – 7.7 MB) |
Statistical (PDF – 959 KB)
Statistical 2 (PDF – 602 KB)
|
PREA |
Insulin aspart injection – Fiasp |
Novo Nordisk Inc. |
CDTL Review (PDF – 1 MB)
Medical (PDF – 3.5 MB)
|
Clinical pharmacology (PDF – 4MB) |
Statistical (PDF – 905KB) |
PREA |
Insulin Degludec – Tresiba |
Novo Nordisk Inc. |
CDTL Review (PDF – 7MB)
Medical (PDF – 7 MB)
|
Clinical pharmacology (PDF – 4MB) |
Statistical (PDF – 905KB) |
PREA |
Insulin Degludec / Insulin Aspart) – Ryzodeg |
Novo Nordisk Inc. |
Medical (PDF – 7 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 905 KB) |
PREA |
Insulin glargine-yfgn – Semglee
|
Mylan Pharmaceuticals Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
Insulin glargine-aglr – Rezvoglar |
Eli Lilly and Company |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Iodixanol – Visipaque |
GE HealthCare Inc.
|
CDTL Review (PDF – 2.4 MB)
Medical (PDF – 1.9 MB)
|
Clinical pharmacology (PDF – 988 KB) |
Statistical (PDF – 1.8 MB) |
PREA |
Iohexol – Oraltag |
Interpharma Praha, a.s. |
Medical (PDF -91 KB) |
Clinical pharmacology (PDF – 294 KB) |
Statistical (PDF – 98 KB) |
PREA |
Ipilimumab – Yervoy |
Bristol-Myers Squibb Company |
Medical (PDF 5.5 MB) |
Clinical pharmacology (PDF – 1.6 MB) |
None |
PREA |
Iron Sucrose Injection, USP – Venofer |
Luitpold Pharmaceuticals, Inc. |
Medical (PDF -2 MB) |
Clinical pharmacology (PDF – 114 KB) |
Statistical (PDF – 576 KB) |
PREA |
Ivabradine – Corlanor |
Amgen Inc. |
CDTL (PDF – 3 MB)
Medical (PDF – 4 MB)
|
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 51 KB) |
BPCA |
Ixekizumab – Taltz |
Eli Lilly and Company |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Kit for the Preparation of Technetium Tc 99m Pentetate Injection – Draximage |
Jubilant DraxImage, Inc |
Medical (PDF – 2 MB) |
None |
Statistical (PDF – 376 KB) |
PREA |
Lacosamide – Vimpat |
UCB, Inc. |
CDTL Review (PDF – 371 KB)
Medical (PDF – 915 KB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA
|
Lacosamide – Vimpat |
UCB, Inc. |
Medical (PDF – 541 KB)
Medical (PDF – 631 KB)
|
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 2 MB) |
PREA |
Lacosamide – Vimpat |
UCB, Inc. |
Medical (PDF – 700 KB) |
Clinical pharmacology (PDF – 800 KB) |
None |
PREA |
Lactic acid citric acid and K bitartrate – Phexxi |
Evofem, Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 KB) |
Statistical (PDF – 3 76706 KB) |
PREA |
Lamivudine – Epivir |
ViiV Healthcare Company |
Medical (PDF -4.2 MB) |
Clinical pharmacology (PDF – 3 MB) |
|
PREA |
Lamivudine and Raltegravir – Dutrebis |
Merck Sharp & Dohme Corp. |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF – 6.4 MB) |
None |
PREA |
Lamivudine and tenofovir – Cimduo |
Mylan Pharmaceuticals India |
Medical (PDF – 73 KMB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Lamivudine and tenofovir disoproxil fumarate – Temixys
|
Celltrion, Inc. |
Medical (PDF – 20 KB)
|
Clinical pharmacology addendum (PDF – 166 KB)
Clinical pharmacology (PDF – 1 MB)
|
None |
PREA |
Lamotrigine – Lamictal |
GlaxoSmithKline LLC |
Medical (PDF -18 MB) |
Clinical pharmacology (PDF – 793 KB) |
Statistical (PDF – 1.8 MB) |
PREA |
Ledipasvir-sofosbuvir – Harvoni |
Gilead Sciences, Inc. |
Medical and CDTL (PDF – 1.5 MB) |
Clinical pharmacology (PDF – 539 KB) |
Statistical (PDF – 205 KB) |
PREA |
Ledipasvir-sofosbuvir – Harvoni |
Gilead Sciences, Inc. |
Medical (PDF – 426 KB) |
None |
None |
PREA |
Ledipasvir-sofosbuvir – Harvoni |
Gilead Sciences, Inc. |
Medical (PDF – 280 KB) |
None |
None |
BPCA |
Leuprolide acetate – Fensolvi |
Tolmar, Inc. |
Medical (PDF – 280 KB) |
Clinical pharmacology (PDF – 3.9 MB |
Statistical (PDF – 2 MB) |
PREA |
Levalbuterol hydrochloride – Xopenex |
Oak Pharmaceuticals |
Medical (PDF -8.3 MB) |
Clinical pharmacology (PDF – 3.9 MB) |
Statistical (PDF – 2 MB) |
PREA |
Levalbuterol tartrate – Xopenex HFA |
Sunovion Pharmaceuticals Inc. |
Medical (PDF -3.9 MB) |
Clinical pharmacology (PDF – 1.2 MB) |
Statistical (PDF 1.3 MB) |
PREA |
Levamlodipine – Conjupri |
CSPC Ouyi Pharmaceutical Co., Ltd. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 569 KB) |
None |
PREA |
Levetiracetam – Keppra Extended Release Tablets |
UCB, Inc. |
DD Summary Review (PDF – 202KB)
CDTL Review (PDF – 371 KB)
Medical (PDF – 327KB)
|
Clinical pharmacology (PDF – 1.2 MB) |
None |
PREA |
Levonorgestrel – Liletta |
Medicines360 |
Medical (PDF – 8.8 MB) |
Clinical pharmacology (PDF – 1M B)
Clinical pharmacology (PDF – 2.4 MB)
|
Statistical (PDF – 1.5 MB) |
PREA |
Levonorgestrel/ethinyl estradiol tablets |
Exeltis |
CDTL (PDF – 8.8 MB)
Medical (PDF – 8.8 MB)
Medical (PDF – 8.8 MB)
|
Clinical pharmacology (PDF – 1M B)
Clinical pharmacology (PDF – 2.4 MB)
|
Statistical (PDF – 1.5 MB) |
PREA |
Levonorgestrel/ethinyl estradiol and ethinyl estradiol – Quartette |
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF -6MB) |
Clinical pharmacology (PDF – 4 MB)
Clinical pharmacology addendum (PDF – 89KB)
|
Statistical (PDF – 1MB) |
PREA |
Levonorgestrel-releasing intrauterine system – Skyla |
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF – 8MB) |
Clinical pharmacology (PDF – 4MB) |
Statistical (PDF – 424 KB) |
PREA |
Levonorgestrel releasing intrauterine system – Liletta
|
Medicines360 |
CDTL Review (PDF – 179KB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 168 KB) |
PREA |
Levonorgestrel – Mirena
|
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Levothyroxine sodium oral solution – Tirosint-SOL |
Cromsource, Inc. |
CDTL Review (PDF – 461 KB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Lipid injectable emulsion – SMOFlipid |
Fresenius Kabi USA, LLC |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Liraglutide – Saxenda
|
Novo Nordisk, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF – 2 MB) |
PREA |
Liraglutide – Victoza |
Novo Nordisk Inc. |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 864 KB) |
Statistical (PDF – 450 KB) |
BPCA |
Lisdexamfetamine dimesylate – Vyvanse |
Shire Development, LLC |
Medical (PDF – 218 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Lisdexamfetamine mesylate – Vyvanse |
Shire |
Medical (PDF – 2 MB) |
None |
Statistical (PDF – 1 MB) |
PREA |
Lisdexamfetamine dimesylate – Vyvanse
|
Takeda Pharmaceuticals U.S.A., Inc. |
Medical (PDF – 804 KB) |
None |
None |
BPCA |
Liisenatide – Adlyxin |
Sanofi-aventis U.S. LLC |
Medical (PDF – 182 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Pitavastatin – Livalo |
Kowa Pharmaceuticals America, Inc. |
CDTL Review (PDF – 526 KB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 240 KB) |
PREA |
Loteprednol – Lotemax |
Bausch & Lonb Inc. |
Medical (PDF – 318 KB)
Medical (PDF – 218 KB)
|
None |
Statistical (PDF – 3 MB) |
PREA |
Luliconazole – LuzuTM |
Medicis Pharmaceutical Corporation, a division of Valeant Pharmaceuticals NA LLC |
CDTL (PDF – 358 KB)
CDTL (PDF – 372 KB)
Medical (PDF – 306 KB)
Medical (PDF – 616 KB)
|
Clinical pharmacology (PDF -1 MB)
Clinical pharmacology (PDF – 423 KB)
|
Statistical (PDF – 207 KB) |
PREA |
Lopinavir / Ritonavir – Kaletra |
AbbVie Inc. |
Medical (PDF – 5.8 MB) |
Clinical pharmacology (PDF -2.3 MB) |
Statistical (PDF – 1.9 MB) |
PREA |
Lubiprostone – Amitizia |
Sucampo Pharmaceuticals Inc. |
Medical (PDF – 11 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 1 MB) |
PREA |
Lurasidone hydrochloride – Latuda |
Sunovion Pharmaceuticals, Inc. |
Medical (PDF – 6 MB)
Medical (PDF – 7 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 369 KB)
Statistical (PDF – 255 KB)
|
PREA |
Lurasidone hydrochloride – Latuda |
Sunovion Pharmaceuticals, Inc. |
CDTL (PDF – 6 MB)
Medical (PDF – 6 MB)
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 368 KB) |
PREA |
Lurasidone hydrochloride – Latuda |
Sunovion Pharmaceuticals, Inc. |
Medical (PDF – 1.0 MB) |
None |
None |
PREA |
Maraviroc – Selzentry |
Viiv Healthcare |
Medical (PDF – 1.0 MB) |
Clinical pharmacology (PDF – 2.8 MB) |
None |
PREA |
Maraviroc – Selzentry |
Viiv Healthcare |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
Memantine hydrochloride – Namenda XR |
Forest Research Institute, Inc. (subsidiary of Forest Laboratories Inc.) |
Medical (PDF – 2.1 MB) |
Clinical pharmacology (PDF – 956 KB) |
Statistical (PDF – 1.1 MB) |
BPCA |
Mepolizumab – Nucala |
GlaxoSmithKline LLC |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 6 MB)
Clinical pharmacology addendum (PDF -425KB)
|
Statistical (PDF – 1.4 MB) |
PREA |
Mepolizumab – Nucala |
GlaxoSmithKline LLC |
Medical(PDF – 8 MB) |
None |
None |
PREA |
Mepolizumab – Nucala |
GlaxoSmithKline LLC |
Medical (PDF – 8 MB) |
None |
None |
PREA |
Mirabegron – Myrbetriq |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 13MB) |
Clinical pharmacology (PDF – 2.8MB)
|
Statistical (PDF – 168KB) |
BPCA |
Mesalamine – Asacol HD |
Warner Chilcott |
Medical (PDF – 6MB) |
Clinical pharmacology (PDF – 3.2 MB)
Clinical pharmacology (PDF – 518 KB)
|
Statistical (PDF -499KB) |
PREA |
Mesalamine – Canasa |
Forest Laboratories |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 251KB) |
Statistical (PDF – 344 KB) |
PREA |
Mesalamine – Delzicol |
Warner Chilcott LLC |
Medical (PDF – 707 KB)
Medical Addendum(PDF – 495 KB)
|
Clinical pharmacology (PDF -116KB) |
None |
PREA |
Mesalamine – Delzicol |
Warner Chilcott (US), LLC |
Medical (PDF – 4.7 MB) |
Clinical pharmacology (PDF – 729 KB) |
Statistical (PDF – 1.1KB) |
PREA |
Mesalamine – Lialda |
Shire Development, LLC |
Medical (PDF – 6 MB) |
|
|
|
Metformin hydrochloride for extended-release oral suspension – Riomet ER
|
Pharmaceutical Industries Limited |
CTDL Review (PDF – 917 KB) |
Clinical pharmacology (PDF – 818 KB) |
None |
PREA |
10% Methyl salicylate, 3% L-menthol – Salonpas Pain Relief |
Hisamitsu Pharmaceutical Co., Inc. |
Medical (PDF – 998 KB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2.6 MB) |
Statistical (PDF – 1.4 MB) |
PREA |
Methylphenidate hydrochloride extended-release – Aptensio XR
|
Rhodes Pharmaceuticals L.P. |
Medical (PDF – 2.3 MB) |
Clinical pharmacology (PDF – 3.6M B) |
Statistical (PDF – 1.1 MB) Statistical (PDF – 629 KB) |
PREA |
Methylphenidate hydrochloride – Quillivant XR |
NextWave Pharmaceuticals, Inc. |
Medical (PDF – 26 KB) |
Clinical pharmacology (PDF – 588 KB) |
Statistical (PDF – 380 KB) |
PREA |
Methylphenidate hydrochloride extended release chewable tablets – QuilliChew ER |
Pfizer Inc. |
CTDL Review (PDF -1.3MB)
Medical (PDF – 4.8 MB)
|
Clinical pharmacology (PDF -2.9MB) |
Statistical (PDF -498KB) |
PREA |
Methylphenidate HCL extended-release capsules – Adhansia XR
|
Purdue Pharma
|
Medical (PDF – 2 MB)
Medical (PDF – 4.8 MB)
|
Clinical pharmacology (PDF – 2 MB)
|
Statistical (PDF – 1 MB)
Statistical (PDF – 2 MB)
|
PREA |
Methylphenidate hydrochloride – Aptensio XR |
Rhodes Pharmaceuticals L.P. |
CTDL Review (PDF – 592 KB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 1 MB)
Statistical (PDF – 139 KB)
|
BPCA |
Methylphenidate hydrochloride – Jornay PM
|
Ironshore Pharmaceuticals & Development, Inc. |
Medical (PDF – 4.8 MB) |
Clinical pharmacology (PDF – 2.1 MB) |
Statistical (PDF – 921 KB) |
PREA |
Methylphenidate extended-release orally disintegrating tablets – Cotempla XR-ODT |
Neos Therapeutics, Inc. |
Medical (PDF – 5.7 MB)
Medical (PDF – 1.2 MB)
|
Clinical pharmacology (PDF – 2.1 MB)
Clinical pharmacology (PDF – 2.1 MB)
|
Statistical (PDF – 921 KB)
Statistical (PDF – 96 KB)
|
PREA |
Methoxy polyethylene glycol-epoetin beta – Mircera |
Vifor International AG |
Medical (PDF – 2.3 MB) |
None |
Statistical (PDF – 239 KB)
|
PREA |
Metoprolol Succinate – KAPSPARGO SPRINKLE |
Sun Sun Pharmaceutical Industries LimitedPharmaceutical Industries Limited |
Medical (PDF – 799 KB) |
Clinical pharmacology (PDF – 978 KB) |
None |
PREA |
Metronidazole vaginal gel 1.3% – Nuvessa |
Chemo Research SL |
Medical (PDF – 1.2 MB) |
Clinical pharmacology (PDF – 70 KB) |
Statistical (PDF – 127 KB) |
PREA |
Micafungin for injection – Mycamine |
Astellas Pharma US, Inc. |
Medical (PDF – 1.2 MB) |
None |
None |
BPCA |
Micafungin sodium – Mycamine |
Astellas Pharma US, Inc. |
Medical (PDF – 2.2 MB) |
Clinical pharmacology (PDF – 4.4MB)
|
Statistical (PDF -987KB) |
BPCA |
Minocycline – Amzeeq |
Foamix Pharmaceuticals Inc. |
Medical (PDF – 2.2 MB) |
None |
None |
PREA |
Mirabegron extended-release tablets and mirabegron extended-release for oral suspension – Myrbetriq and Myrbetriq Granules |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 13 MB) |
None |
None |
BPCA |
Mixed salts of a single-entity amphetamine product – Mydayis |
Shire Development, LLC. |
Medical (PDF – 6.8 MB)
|
Clinical pharmacology (PDF -1.8KB) |
Statistical (PDF -987KB) |
PREA |
Mixed salts of a single entity amphetamine product – Mydayis |
Shire Development, LLC. |
Medical (PDF – 6.8 MB) |
None |
None |
BPCA |
Mometasone furoate – Asmanex HFA |
Merck Sharp & Dohme Corp. |
Medical (PDF -2.7MB) |
Clinical pharmacology (PDF -1.5MB) |
Statistical (PDF -603KB) |
PREA |
Mometasone furoate – Asmanex HFA |
Merck Sharp & Dohm Corp |
Medical (PDF-1MB) |
None |
None |
PREA |
Mometasone furoate and formoterol fumarate – Dulera |
Schering-Plough |
Medical (PDF-1MB) |
None |
None |
PREA |
Morphine sulfate injection |
Hospira, Inc. |
CDTL (PDF – 2 MB) |
None |
None |
PREA |
Moxifloxacin – Avelox
|
Bayer Pharmaceuticals |
Medical (PDF- 905KB) |
Clinical pharmacology (PDF -1.8MB) |
Statistical (PDF – 760KB) |
PREA |
Moxifloxacin ophthalmic solution – Vigamox |
Alcon Pharmaceuticals, Ltd. |
Medical (PDF – 434 KB)
DD Summary Review (PDF- 118 KB)
|
None |
None |
BPCA |
Naftifine hydrochloride – Naftin |
Merz Pharmaceuticals, LLC |
Medical (PDF – 488 KB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 188 KB) |
PREA |
Naftifine hydrochloride – Naftin Cream, 2% |
Merz Pharmaceuticals, LLC |
Medical (PDF – 1.2MB) |
Clinical pharmacology (PDF -1.6MB) |
Statistical (PDF – 822KB) |
PREA |
Naloxone hydrochloride – Narcan Nasal Spray |
Adapt Pharma Operations Limited |
DD Summary Review(PDF -1.2MB)
CTDL Review (PDF -3MB)
|
Clinical pharmacology (PDF -1.5MB) |
None |
PREA |
Naloxone Hydrochloride Injection – Naloxone Hydrochloride Injection |
Kaleo, Inc. |
CDTL Review (PDF – 2 MB) |
Clinical pharmacology (PDF – 4 MB) |
None |
PREA |
Naloxone hydrochloride – Zimhi
|
Adamis Pharmaceuticals Corporation |
CDTL Review (PDF – 2 MB) |
Clinical pharmacology (PDF – 368 KB) |
None |
PREA |
Naproxen sodium 220 mg and Diphenhydramine hydrochloride – Aleve PM |
Bayer HealthCare, LLC – Consumer Care |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -1.7MB) |
Statistical (PDF -1.3MB) |
PREA |
Naproxen and esomeprazole magnesium – Vimovo |
Horizon Pharma Inc. |
Medical (PDF – 3.8 MB) |
Clinical pharmacology (PDF -2.3 MB) |
None |
PREA |
Neostigmine methylsulfate – Bloxiverz |
Eclat Pharmaceuticals, LLC |
Medical (PDF -7.7MB) |
Clinical pharmacology (PDF -2MB) |
None |
PREA |
Nevirapine – Viramune XR |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF -2MB) |
Clinical pharmacology (PDF -446KB) |
Statistical (PDF – 723KB) |
PREA |
Nilotinib – Tasigna |
Sponsor: Novartis Pharmaceuticals Corporation |
Medical (PDF – 1.2 MB) |
Clinical pharmacology (PDF – 1.6 MB) |
Statistical (PDF – 124 KB) |
BPCA |
Nitisinone – NITYR |
Cycle Pharmaceuticals Ltd. |
Medical (PDF – 358 KB) |
Clinical pharmacology (PDF – 3.6 MB) |
None |
PREA |
Nitisinone – NITYR |
Cycle Pharmaceuticals Ltd. |
Medical (PDF – 358 KB) |
None |
None |
PREA |
Nivolumab – Opdivo |
Bristol-Myers Squibb Company |
DD (PDF – 188 KB)
Medical (PDF – 222 KB)
|
Clinical pharmacology (PDF – 202 KB)
Clinical pharmacology (PDF – 250 KB)
|
Noen |
PREA |
Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules – Taytulla |
Warner Chilcott Company, LLC |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -3.2MB) |
Statistical (PDF – 469KB) |
PREA |
Obiltoxaximab – Anthim |
Elusys Theraputics, Inc. |
Medical (PDF -18MB)
Addendum (PDF -249KB)
|
Clinical pharmacology (PDF -12MB)
Addendum (PDF -126KB)
|
Statistical (PDF – 9MB) |
PREA |
Ocriplasmin- Jetrea |
ThromboGenics, Inc. |
Medical (PDF – 817KB) |
Clinical pharmacology (PDF – 117KB) |
Statistical (PDF – 760KB) |
PREA |
Olanzapine and fluoxetine hydrochloride – Symbyax |
Eli Lilly and Company |
Medical (PDF -1.3MB) |
Clinical pharmacology (PDF -1.2MB)
Addendum (PDF – 132KB)
|
Statistical (PDF – 953KB) |
PREA |
Olopatadine – Pazeo |
Alcon Research LTD |
Medical (PDF -2.3MB) |
Clinical pharmacology (PDF -340KB) |
Statistical (PDF – 4.3KB) |
BPCA |
Omalizumab – Xolair |
Genentech |
Medical (PDF -6MB) |
Clinical pharmacology (PDF -1.3MB) |
Statistical (PDF – 2MB) |
PREA |
Omalizumab – Xolair |
Genentech, Inc. and Novartis Pharmaceuticals Corp. |
Medical (PDF-4MB) |
Clinical pharmacology (PDF -1MB) |
Statistical (PDF-1 MB) |
PREA |
Omalizumab – Xolair
|
Genentech, Inc. and Novartis Pharmaceuticals Corp. |
Medical (PDF – 5MB) |
None |
None |
PREA |
Omeprazole magnesium – Prilosec |
AstraZeneca Pharmaceuticals LP |
Medical (PDF -908KB) |
Clinical pharmacology (PDF -1.6MB) |
None |
PREA |
OnabotulinumtoxinA – Botox
|
Allergan, Inc. |
CDTL (PDF – 403 KB)
Medical (PDF – 1 MB)
|
None |
Statistical (PDF – 173 KB) |
PREA |
OnabotulinumtoxinA – Botox |
Allergen, Inc |
Medical (PDF – 3 MB)
Medical (PDF – 1 MB)
|
None |
Statistical (PDF – 1 MB) |
PREA |
OnabotulinumtoxinA – Botox |
Allergen, Inc |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Oxcarbazepine – Oxtellar XR |
Supernus Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 7 MB) |
Statistical (PDF – 482 KB) |
PREA |
Oxycodone hydrochloride – Oxycontin |
Purdue Pharma L.P. |
Medical (PDF – 17 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 678 KB) |
BPCA |
Oxycodone hydrochloride – OxyContin |
Purdue Pharma L.P. |
Medical (PDF – 17 MB) |
Clinical pharmacology (PDF – 16 MB) |
Statistical (PDF – 551 KB) |
BPCA |
Oxymorphone – Opana |
|
Medical (PDF – 17 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
Ozenoxacin – Xepi |
Ferrer Internacional S.A. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 524 KB) |
PREA |
Paclitaxel – Abraxane |
Abraxis BioScience, L.L.C., a wholly-owned subsidiary of Celgene Corporation |
Medical (PDF – 235 KB) |
None |
None |
BPCA |
Palifermin – Kepivance |
Quintiles, Inc. |
Medical (PDF – 280 KB) |
Clinical pharmacology (PDF – 726 KB) |
None |
PREA |
Palonosetron hydrochloride – Aloxi |
Helsinn Healthcare SA |
Medical (PDF -15MB)
Medical (PDF -2MB)
|
Clinical pharmacology (PDF -2.3MB) |
Statistical (PDF – 771KB) |
BPCA |
Pancrelipase – Creon |
AbbVie Inc. |
Medical (PDF -566KB) |
None |
None |
PREA |
Pancrelipase – Pancreaze |
Janssen Pharmaceuticals, Inc. |
Medical (PDF -142KB) |
None |
None |
PREA |
Pancrelipase – Pertzye |
Digestive Care, Inc. |
Medical (PDF – 1MB) |
None |
None |
PREA |
Pancrelipase – Zenpep |
Aptalis Pharma Limited. |
Medical (PDF -587KB) |
None |
None |
PREA |
Paricalcitol – Zemplar |
AbbVie Inc. |
Medical (PDF – 3.0MB)
CDTL (PDF – 1.1MB)
|
Clinical pharmacology (PDF – 1.9MB) |
Statistical (PDF – 427KB) |
PREA |
Pegfilgrastim-cbqv – UDENYCA
|
Coherus BioSciences, Inc
|
Medical (PDF – 184 KB)
Medical (PDF – 228 KB)
CDTL (PDF – 584 KB)
|
Clinical pharmacology (PDF – 968 KB) |
Statistical (PDF – 199 KB) |
PREA |
Peginterferon alfa-2a – Pegays |
Hoffmann-La Roche, Incorporated |
Medical (PDF – 799 KB) |
Clinical pharmacology (PDF – 667 KB) |
Statistical (PDF – 667 KB) |
PREA |
Peramivir – Rapivab |
BioCryst Pharmaceuticals, Inc. |
Medical (PDF – 767KB |
Clinical pharmacology (PDF -468 KB) |
Statistical (PDF – 767KB) |
PREA |
Peramivir – Rapivab |
BioCryst Pharmaceuticals, Inc. |
Medical (PDF – 1 MB |
Clinical pharmacology (PDF – 81 KB) |
None |
PREA |
Perampanel – Fycompa |
Eisai, Inc. |
Medical (PDF -4.8MB) |
Clinical pharmacology (PDF -6MB) |
Statistical (PDF -1.2MB) |
PREA |
Perampanel – Fycompa |
Eisai, Inc. |
Medical (PDF -2.9MB) Medical (PDF -1.6MB) |
Clinical pharmacology (PDF -4MB) |
Statistical (PDF -1.3MB) |
PREA |
Perampanel – Fycompa |
Eisai Inc. |
Medical (PDF -2.6MB)
Medical MTL (PDF -678KB)
|
Clinical pharmacology (PDF -1.2MB) |
None |
PREA |
Perampanel – Fycompa |
Eisai Inc. |
Medical (PDF – 79 KB) |
Clinical pharmacology (PDF – 86 KB) |
None |
PREA |
Perampanel – Fycompa
|
Eisai Inc.
|
CDTL (PDF – 452 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 2.5 MB) |
None |
PREA |
Phentolamine mesylate – OraVerse |
Septodont Holding Sas |
Medical (PDF -2.7MB) |
None |
Statistical (PDF -1.4MB) |
PREA |
Phenylephrine hydrochloride ophthalmic solution |
Paragon BioTeck, Inc. |
Medical (PDF – 1MB) |
Clinical pharmacology (PDF – 95KB) |
Statistical (PDF -1MB) |
PREA |
Phenylephrine and ketorolac – Omidria |
Omeros Corporation |
CDTL (PDF – 1 MB) Medical (PDF – 4 MB) |
None |
Statistical (PDF – 816 KB) |
BPCA |
Piperacillin and tazobactam – Zosyn |
Wyeth Pharmaceuticals LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Pitavastatin – Livalo
|
Kowa Pharmaceuticals America, Inc. |
CDTL Review (PDF – 526 KB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 240 KB) |
BPCA |
Pomalidomide – POMALYST |
Celgene Corporation |
Medical (PDF – 15 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BPCA |
Posaconazole – Noxafil |
Merck Sharp & Dohme Corp. |
Medical (PDF – 3MB) |
Clinical pharmacology (PDF – 1.2MB) |
Statistical (PDF – 252KB) |
PREA |
Posaconazole – Noxafil |
Merck |
Medical (PDF – 602KB) |
Clinical pharmacology (PDF – 645KB) |
None |
PREA |
Potassium phosphate |
Fresenius Kabi USA, LLC |
Medical (PDF – 602KB) |
None |
None |
PREA |
Prasugrel – Effient |
Eli Lilly and Company |
Medical (PDF – 2MB) |
Clinical pharmacology (PDF – 911KB) |
Statistical (PDF -290KB) |
BPCA |
Pregabalin – Lyrica |
Pfizer |
Medical (PDF – 3.8MB) |
Clinical pharmacology (PDF – 5.9KB) |
Statistical (PDF – 825KB) |
PREA |
Pregabalin – Lyrica |
PF PRISM CV |
Medical and Statistical (PDF – 1.2 MB) |
Clinical pharmacology (PDF – 1.3 MB) |
Medical and Statistical (PDF – 1.2 MB) |
PREA |
Pregabalin – Lyrica |
Pfizer |
CTDL Review (PDF – 1 MB)
Medical (PDF – 1 MB)
|
Clinical pharmacology(PDF -1 MB) |
Statistical (PDF – 2 MB) |
PREA |
Quetiapine fumarate – Seroquel and Seroquel XR |
AstraZeneca Pharmaceuticals LP |
CTDL Review (PDF -1MB)
Medical (PDF – 3MB)
|
Clinical pharmacology(PDF -1.8MB)
Clinical pharmacology (PDF -739KB)
|
Statistical (PDF -785KB) |
PREA |
Rabeprazole sodium – AcipHex Sprinkle |
Eisa Inc. |
Medical (PDF – 3MB) |
Clinical pharmacology (PDF – 5MB) |
Statistical (PDF 185KB) |
BPCA |
Ramucirumab – Cyramz
|
Eli Lilly and Company |
Medical (PDF – 198 KB) |
Clinical pharmacology (PDF – 168 KB) |
None |
BPCA |
Raltegravir – Isentress |
Merck Sharp Dohme Corp |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -2 MB) |
None |
PREA |
Raltegravir – Isentress |
Merck Sharp Dohme Corp |
CDTL Review (PDF – 4.5 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF 874 KB) |
PREA |
Raltegravir – Isentress |
Merck Sharp Dohme Corp |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Ravulizumab-cwvz – Ultomiris
|
Alexion Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
Remdesivir – Veklury |
Gilead Sciences, Inc. |
Medical (PDF – 1 MB)
Medical (PDF – 776 KB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 225 KB)
Statistical (PDF – 782 KB)
|
PREA |
Reslizumab – Cinqair |
Teva Respiratory, LLC |
Medical (PDF -5MB) |
Clinical pharmacology (PDF – 9 MB) |
Statistical (PDF -1.6MB) |
PREA |
Rifapentin – Priftin |
Sanofi US Services Inc. |
Medical (PDF -10.1MB) |
Clinical pharmacology (PDF -5.1MB) |
Statistical (PDF -3.1MB) |
PREA |
Rilpivirine – Edurant |
Janssen Products L.P. |
Medical (PDF -2.3MB) |
Clinical pharmacology (PDF -138KB) |
None |
PREA |
Rivaroxaban – Xarelto |
Janssen Pharmaceuticals, Inc. |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF – 10 MB) |
Statistical (PDF – 797 KB) |
BPCA |
Risperidone – Risperdal Consta |
Janssen Pharmaceuticals, Inc. |
DD Summary Review (PDF -20KB)
CTDL Review (PDF -1MB)
Medical (PDF -670KB)
Medical (PDF -667KB)
|
None |
Statistical (PDF -237KB) |
PREA |
Rituximab-arrx – Riabni
|
Amgen, Inc. |
Medical (PDF – 7 MB) |
None |
None |
PREA |
Rufinamide – Banzel |
Eisai Inc. |
Medical (PDF -9.4MB) |
Clinical pharmacology (PDF -3MB) |
None |
BPCA |
Ruxolitinib – Jakafi |
Incyte Corporation |
Medical (PDF – 685 KB) |
Clinical pharmacology (PDF – 533 KB) |
None |
BPCA |
Ruxolitinib – OPZELURA
|
Incyte Corporation |
Medical (PDF – 9 MB) |
None |
None |
PREA |
Sacubitril-valsartan – Entresto |
Novartis Pharmaceuticals Corp. |
Medical (PDF – 685 KB) |
Clinical pharmacology (PDF – 533 KB) |
Statistical (PDF -1MB) |
BPCA |
Sapropterin dihydrochloride – Kuvan |
BioMarin Pharmaceutical Inc. |
Medical (PDF -3.6MB) |
Clinical pharmacology (PDF -2.5MB) |
None |
BPCA |
Saquinavir mesylate – Invirase |
Hoffmann La-Roche, Inc.orporated c/o Genentech, Inc. |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -1.5MB) |
Statistical (PDF -1MB) |
PREA |
Sarecycline – Seysara
|
Allergan, Inc. |
Medical (PDF -1MB) |
None |
None |
PREA |
Secnidazole – SOLOSEC |
Lupin Pharmaceuticals, Inc. |
Medical (PDF 4 1MB) |
None |
None |
PREA |
Secukinuma – Cosentyx
|
Novartis Pharmaceuticals Corporation |
Medical (PDF – 6 MB) |
None |
None |
PREA |
Selegiline – Emsam |
Somerset Pharmaceuticals |
Medical (PDF -1.1MB)
Medical 2 (PDF -1.2MB)
Medical Secondary 1 (PDF -349KB)
Medical Secondary 2 (PDF -188KB)
|
None |
None |
PREA |
Selenious Acid – Selenious Acid |
American Regent, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
Segesterone acetate and ethinyl estradiol vaginal systems – Annovera |
The Population Council, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
Serdexmethylphenidate chloride (SDX Cl) & Dexmethylphenidate hydrochloride (d-MPH HCL) – Azstarys |
Commave Therapeutics SA |
Multidisciplinary (PDF – 6 MB) |
None |
None |
PREA |
Sevelamer Carbonate – Renvela |
Genzyme/Sanofi |
Medical (PDF – 745KB) |
Clinical pharmacology (PDF – 542KB) |
Statistical (PDF – 541KB) |
PREA |
Sitagliptin – Januvia, Janumet & Janumet XR
|
Merck Sharp & Dohme Corp.: |
CDTL (PDF – 1 MB)
Medical (PDF – 4 MB)
|
Clinical pharmacology (PDF – 339 KB) |
Statistical (PDF – 623 KB) |
BOTH |
Sildenafil – Revatio |
Pfizer, Inc. |
Medical (PDF – 6MB) |
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -508KB) |
BOTH |
Sodium picosulfate, magnesium oxide, and anhydrous citric acid – Prepopik |
Ferring Pharmaceuticals Inc. |
Medical (PDF – 193 KB) |
None |
None |
PREA |
Sodium sulfate, potassium sulfate, and magnesium sulfate – Suprep Bowel Prep Kit |
Sponsor: Braintree Laboratories, Inc. |
Medical (PDF – 193 KB) |
None |
None |
PREA |
Sodium picosulfate, magnesium oxide and anhydrous citric acid – Clenpiq
|
Ferring Pharmaceuticals Inc.
|
CDTL (PDF – 1 MB) |
None |
None |
PREA |
Spinosad – Natroba |
ParaPRO, LLC |
Medical (PDF – 854KB) |
Clinical pharmacology (PDF -171KB) |
None |
PREA |
Sofosbuvir – Sovaldi |
Gilead Sciences, Inc. |
Medical and CDTL (PDF – 345 KB) |
Clinical pharmacology (PDF – 511 KB) |
None |
PREA |
Sofosbuvir – Sovaldi |
Gilead Sciences, Inc. |
Medical (PDF – 218 K) |
None |
None |
PREA |
Sofosbuvir and velpatasvir – Epclusa |
Gilead Sciences, Inc. |
Medical (PDF – 218 K) |
Clinical pharmacology (PDF – 511 KB) |
None |
PREA |
Sofosbuvir and velpatasvir – Epclusa |
Gilead Sciences, Inc. |
Medical (PDF – 287 KB) |
Clinical pharmacology (PDF – 4 MB) |
None |
BPCA |
Solifenacin succinate – VESIcare |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 933KB) |
Statistical (PDF – 960 KB) |
PREA |
Solifenacin succinate – VESIcare |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 3MB)
CDTL (PDF – 1.1MB)
|
Clinical pharmacology (PDF -2MB) |
Statistical (PDF – 960 KB) |
PREA |
Spinosad – Natroba |
ParaPRO LLC |
Medical (PDF – 458 KB) |
None |
None |
PREA |
Sulfur Hexafluoride Lipid-Type A Microspheres) for Injectable Suspension – Lumason |
Bracco Diagnostics Inc. |
Medical (PDF – 5.1MB) |
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -792KB) |
PREA |
Sulfur Hexafluoride Lipid-Type A Microspheres – Lumason |
Bracco Diagnostics, Inc. |
Medical (PDF – 3MB)
CDTL (PDF – 1.1MB)
|
Clinical pharmacology (PDF – 1MB) |
Statistical (PDF – 859KB) |
PREA |
Sulfur Hexafluoride Lipid-Type A Microspheres – Lumason |
Bracco Diagnostics, Inc. |
Medical (PDF -1.8MB) |
Clinical pharmacology (PDF -2.8MB) |
Statistical (PDF -843KB) |
PREA |
Sugammadex – Bridion |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
Medical (PDF – 3 MB |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
BPCA |
Sumatriptan/Naproxen – Treximet |
Pernix Therapeutics |
Medical (PDF -1.8MB) |
Clinical pharmacology (PDF -2.8MB) |
Statistical (PDF -843KB)
Statistical Addendum (PDF -702KB)
|
BPCA |
Sunitinib malate – Sutent |
C.P. Pharmaceuticals International C.V. |
CDTL (PDF – 680 KB) |
None |
None |
PREA |
Tacrolimus – Astagraf XL |
Astellas Pharma US, Inc.
|
Medical (PDF – 749 KB) |
None |
None |
PREA |
Tadalafil – Cialis |
Eli Lilly and Company |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1.4MB) |
None |
BPCA |
Tavaborole – Kerydin |
Anacor Pharmaceuticals, Inc. |
Multi-disciplinary review (PDF – 2.5 MB) |
None |
None |
PREA |
Tazarotene – Aralzo |
Bausch Health US, LLC |
Clinical (PDF – 1 MB) |
None |
None |
PREA |
Tbo-filgrastim – Granix |
Sicor Biotech UAB c/o Teva Branded Pharmaceutical Products R&D |
CDTL (PDF – 176 KB)
Clinical (PDF – 196 KB)
|
Clinical pharmacology (PDF – 434 KB) |
None |
BPCA |
Technetium 99m Tilmanocept – Lymphoseek |
Cardinal Health 414, LLC |
Multidisciplinary (PDF – 2.2MB) |
None |
None |
PREA |
Tedizolid phosphate – Sivextro |
Cubist Pharmaceuticals, LLC |
Medical (PDF – 9 MB) |
None |
None |
PREA |
Teduglutide – Gattex |
Shire-NPS Pharmaceuticals, Inc. |
Medical (PDF – 9 MB) |
None |
None |
BOTH |
Tenofovir disoproxil fumarate – Viread |
Gilead Sciences |
Medical (PDF – 2.4MB) |
Clinical pharmacology (PDF – 1.4MB) |
Statistical (PDF – 1.4MB) |
PREA |
Tenofovir disoproxil fumarate – Viread |
Gilead Sciences |
CDTL (PDF – 873 KB) |
Clinical pharmacology (PDF – 180 KB) |
Statistical (PDF – 149 KB) |
PREA |
Tenofovir disoproxil fumarate – Viread |
Gilead Sciences |
CDTL (PDF – 349 KB) |
Clinical pharmacology (PDF – 1.7 MB) |
Statistical (PDF – 148 KB) |
PREA |
Teriflunomide – Aubagio |
Sanofi |
CTDL (PDF – 3.3MB)
Clinical (PDF – 3.4MB)
|
Clinical pharmacology (PDF – 1.5MB) |
Statistical (PDF – 410KB) |
BOTH |
Tetracaine hydrochloride – None |
Alcon Research, Ltd. |
DD Medical Summary (PDF -1.8MB)
Medical (PDF -1.4MB)
|
Clinical pharmacology (PDF – 158KB) |
Statistical (PDF – 2.3MB) |
PREA |
Tetracaine HCl and Oxymetazoline HCl – Kovanaze |
St. Renatus, LLC |
Medical (PDF – 11.8MB) |
Clinical pharmacology (PDF – 11.6MB) |
Statistical (PDF – 2.4MB) |
PREA |
Tezepelumab -Tezspir
|
AstraZeneca |
Medical (PDF – 10 MB) |
None |
None |
PREA |
Ticagrelor – Brilinta NEW |
AstraZeneca Pharmaceuticals LP |
Medical (PDF – 10 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 325 KB) |
BPCA |
Tilmanocept – Lymphoseek |
Cardinal Health 414, LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Tiotropium bromide – Spiriva Respimat |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF -11.9MB)
Medical Addendum (PDF – 418KB
|
Clinical pharmacology (PDF – 5.9MB) |
Statistical (PDF – 1.3MB)
Statistical Addendum (PDF -327 KB)
|
PREA |
Tiotropium bromide – Spiriva Respimat |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 4.8MB) |
Clinical pharmacology (PDF – 2MB) |
Statistical (PDF – 432K B) |
PREA |
Tobramycin 300 mg/4mL inhalation solution – Bethkis |
Cornerstone Therapeutics |
Medical (PDF – 5.4MB) |
Clinical pharmacology (PDF – 78KB) |
Statistical (PDF – 687 KB) |
PREA |
Tocilizumab – Actemra
|
Genentech, Inc. |
Medical (PDF – 72 KB)
Medical (PDF – 109 KB)
|
Clinical pharmacology (PDF – 195 KB) |
None |
PREA |
Tocilizumab – Actemra
|
Genentech, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
Tofacitinib – Xeljanz |
Pfizer, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
Topiramate – Topamax |
Janssen Pharmaceuticals, Inc. |
Medical (PDF – 8.6MB) |
None |
Statistical (PDF – 881KB) |
PREA |
Topiramate – Eprontia
|
Azurity Pharmaceuticals, Inc. |
Medical (PDF – 669 KB) |
Clinical pharmacology (PDF – 565 KB) |
None |
PREA |
Trabectedin – Yondelis |
Janssen Products, LP |
Medical (PDF – 2.5 MB) |
Clinical pharmacology (PDF – 683 KB) |
None |
BPCA |
Trace elements injection 4 – Tralement |
American Regent, Inc. |
Medical (PDF – 2.5 MB) |
None |
None |
PREA |
Trace elements injection 4 – Multrys |
American Regent, Inc. |
Medical (PDF – 321 MB) |
None |
None |
PREA |
Tranexamic acid – Lysteda |
Ferring Pharmaceuticals, Inc. |
None |
Clinical pharmacology (PDF – 1.2MB) |
None |
PREA |
Tretinoin lotion – Altreno |
Dow Pharmaceutical Sciences, Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
Tretinoin and benzoyl peroxide – Twyneo |
Sol-Gel Technologies Ltd. c/o B&H Consulting Services Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Trifarotene – Akli |
Galderma Research and Development, LLC |
Medical (PDF – 3 MB) |
None |
None |
PREA |
Upadacitinib – Rinvoq |
AbbVie Inc. |
Medical (PDF – 10 MB) |
None |
None |
PREA |
Ustekinumab – Stelara |
Janssen Biotech, Inc. |
Medical (PDF – 352 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
Valganciclovir hydrochloride – Valcyte |
Roche Palo Alto LLC c/o Genentech, Inc.orporated |
Medical (PDF -2 .7MB) |
Clinical pharmacology (PDF – 6MB) |
None |
PREA |
Valsartan – Diovan
|
Novartis Pharmaceuticals Corporation |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Varenicline – Chantix
|
PF Prism C V |
None |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
Vilazodone hydrochloride – Viibryd |
Allergan Sales, LLC |
Medical (PDF – 3 MB) |
None |
None |
BPCA |
Vortioxetine – Trintellix
|
Takeda Pharmaceuticals, USA, Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
Ustekinumab – Stelara |
Janssen Biotech Inc. |
CDTL (PDF – 593 KB)
Medical (PDF – 5.2 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 275 KB) |
PREA |
Vigabatrin – Sabril |
Lundbeck LLC. |
Medical (PDF – 4MB) |
Clinical pharmacology (PDF – 2.3MB) |
Statistical (PDF – 698KB) |
BOTH |
Viloxazine extended release capsules – Qelbree |
Supernus Pharmaceuticals, Inc. |
Medical (PDF – 13 KB)
Medical (PDF – 13 MB)
|
None |
None |
PREA |
Voriconazole – Vfend |
PF PRISM C.V. |
Medical (PDF – 2 MB)
Medical PDF – 200 KB)
|
Clinical Pharmacology (PDF – 1 MB) |
Statistical (PDF – 200 KB) |
PREA |
Zepatier (elbasvir and grazoprevir) |
Merck Sharpe & Dohme Corp |
Medical (PDF – 838 KB) |
Clinical Pharmacology (PDF – 272 KB) |
|
PREA |
Zinc sulfate – None |
American Regent, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Ziprasidone – Geodon |
Viatris Specialty LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Zolmitriptan – Zomig |
AstraZeneca Pharmaceuticals LP |
Medical (PDF -4.5MB) |
None |
Statistical (PDF -2.9MB) |
PREA |
prea.pdf’>prea.pdf
Fonte/Source: http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-prea-2012-present